{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:21:51Z","timestamp":1792142511634,"version":"4.4.0"},"reference-count":40,"publisher":"American Diabetes Association","issue":"5","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":3059,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,5,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>This multicenter, open-label, parallel-arm study compared the efficacy and safety of exenatide once weekly (EQW) with titrated insulin detemir in patients with type 2 diabetes inadequately controlled with metformin (with or without sulfonylureas).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Patients were randomized to EQW (2 mg) or detemir (once or twice daily, titrated to achieve fasting plasma glucose \u22645.5 mmol\/L) for 26 weeks. The primary outcome was proportion of patients achieving A1C \u22647.0% and weight loss \u22651.0 kg at end point, analyzed by means of logistic regression. Secondary outcomes included measures of glycemic control, cardiovascular risk factors, and safety and tolerability.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Of 216 patients (intent-to-treat population), 111 received EQW and 105 received detemir. Overall, 44.1% (95% CI, 34.7\u201353.9) of EQW-treated patients compared with 11.4% (6.0\u201319.1) of detemir-treated patients achieved the primary outcome (P &amp;lt; 0.0001). Treatment with EQW resulted in significantly greater reductions than detemir in A1C (least-square mean \u00b1 SE, \u22121.30 \u00b1 0.08% vs. \u22120.88 \u00b1 0.08%; P &amp;lt; 0.0001) and weight (\u22122.7 \u00b1 0.3 kg vs. +0.8 \u00b1 0.4 kg; P &amp;lt; 0.0001). Gastrointestinal-related and injection site\u2013related adverse events occurred more frequently with EQW than with detemir. There was no major hypoglycemia in either group. Five (6%) patients in the EQW group and six (7%) patients in the detemir group experienced minor hypoglycemia; only one event occurred without concomitant sulfonylureas (detemir group).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Treatment with EQW resulted in a significantly greater proportion of patients achieving target A1C and weight loss than treatment with detemir, with a low risk of hypoglycemia. These results suggest that EQW is a viable alternative to insulin detemir treatment in patients with type 2 diabetes with inadequate glycemic control using oral antidiabetes drugs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc12-1333","type":"journal-article","created":{"date-parts":[[2012,12,29]],"date-time":"2012-12-29T07:19:30Z","timestamp":1356765570000},"page":"1368-1376","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":68,"title":["Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir"],"prefix":"10.2337","volume":"36","author":[{"given":"Melanie","family":"Davies","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Sciences, University of Leicester, Leicester, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Heller","sequence":"additional","affiliation":[{"name":"Academic Unit of Diabetes, Endocrinology and Metabolism, The University of Sheffield, Sheffield, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seamus","family":"Sreenan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Royal College of Surgeons in Ireland, Connolly Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Sapin","sequence":"additional","affiliation":[{"name":"Lilly France, Suresnes C\u00e9dex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omolara","family":"Adetunji","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Basingstoke, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Tahbaz","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Basingstoke, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiten","family":"Vora","sequence":"additional","affiliation":[{"name":"Diabetes Centre, Royal Liverpool University Hospitals, Liverpool, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2013,4,13]]},"reference":[{"key":"2022031220062681300_B1","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-012-2534-0","article-title":"Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"55","author":"Inzucchi","year":"2012","journal-title":"Diabetologia"},{"key":"2022031220062681300_B2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4158\/EP.15.6.540","article-title":"Statement by an American Association of Clinical Endocrinologists\/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control","volume":"15","author":"Rodbard","year":"2009","journal-title":"Endocr Pract"},{"key":"2022031220062681300_B3","unstructured":"International Diabetes Federation (IDF) Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels: International Diabetes Federation, 2005. Available from http:\/\/www.idf.org\/webdata\/docs\/IDF%20GGT2D.pdf. Accessed October 26, 2012"},{"key":"2022031220062681300_B4","unstructured":"NICE clinical guideline 87. Type 2 diabetes: The management of type 2 diabetes. May 2009. Available from http:\/\/www.nice.org.uk\/nicemedia\/live\/12165\/44320\/44320.pdf. Accessed October 26, 2012"},{"key":"2022031220062681300_B5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","article-title":"Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial","volume":"376","author":"Bergenstal","year":"2010","journal-title":"Lancet"},{"key":"2022031220062681300_B6","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"key":"2022031220062681300_B7","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/S0140-6736(10)60406-0","article-title":"Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial","volume":"375","author":"Diamant","year":"2010","journal-title":"Lancet"},{"key":"2022031220062681300_B8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2337\/dc11-1107","article-title":"Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study","volume":"35","author":"Russell-Jones","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031220062681300_B9","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1464-5491.2009.02752.x","article-title":"Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily","volume":"26","author":"Best","year":"2009","journal-title":"Diabet Med"},{"key":"2022031220062681300_B10","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1001\/archinte.166.17.1836","article-title":"Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus","volume":"166","author":"Ho","year":"2006","journal-title":"Arch Intern Med"},{"key":"2022031220062681300_B11","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1023\/B:PHAM.0000036926.54824.37","article-title":"The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin","volume":"21","author":"Havelund","year":"2004","journal-title":"Pharm Res"},{"key":"2022031220062681300_B12","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1464-5491.2008.02483.x","article-title":"Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial","volume":"25","author":"Fajardo Monta\u00f1ana","year":"2008","journal-title":"Diabet Med"},{"key":"2022031220062681300_B13","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2337\/dc05-1365","article-title":"A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes","volume":"29","author":"Hermansen","year":"2006","journal-title":"Diabetes Care"},{"issue":"7","key":"2022031220062681300_B14","first-page":"CD006383","article-title":"Insulin detemir versus insulin glargine for type 2 diabetes mellitus","author":"Swinnen","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2022031220062681300_B15","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1056\/NEJMoa0905479","article-title":"Three-year efficacy of complex insulin regimens in type 2 diabetes","volume":"361","author":"Holman","year":"2009","journal-title":"N Engl J Med"},{"key":"2022031220062681300_B16","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1056\/NEJMoa075392","article-title":"Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes","volume":"357","author":"Holman","year":"2007","journal-title":"N Engl J Med"},{"key":"2022031220062681300_B17","unstructured":"World Medical Association. Declaration of Helsinki: Ethical principles for medical research involving human subjects [article online], 2008. Available from http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/index.html. Accessed October 26, 2012"},{"key":"2022031220062681300_B18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/BF00449916","article-title":"Evaluating the psychometric characteristics of the Psychological General Well-Being Index with a new response scale","volume":"5","author":"Revicki","year":"1996","journal-title":"Qual Life Res"},{"key":"2022031220062681300_B19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/oby.2001.13","article-title":"Development of a brief measure to assess quality of life in obesity","volume":"9","author":"Kolotkin","year":"2001","journal-title":"Obes Res"},{"key":"2022031220062681300_B20","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/dc11-0098","article-title":"Insulin detemir reduces weight gain as a result of reduced food intake in patients with type 1 diabetes","volume":"34","author":"Zachariah","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031220062681300_B21","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/j.1464-5491.2007.02279.x","article-title":"Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK","volume":"24","author":"Rubino","year":"2007","journal-title":"Diabet Med"},{"key":"2022031220062681300_B22","first-page":"455","article-title":"Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study","volume":"57","author":"Calvert","year":"2007","journal-title":"Br J Gen Pract"},{"key":"2022031220062681300_B23","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1463-1326.2009.01154.x","article-title":"Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study","volume":"11","author":"Davies","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"2022031220062681300_B24","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-143-8-200510180-00006","article-title":"Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial","volume":"143","author":"Heine","year":"2005","journal-title":"Ann Intern Med"},{"key":"2022031220062681300_B25","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2337\/dc11-1233","article-title":"Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks","volume":"35","author":"Diamant","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031220062681300_B26","first-page":"A265","article-title":"Exenatide once weekly: sustained improvement in glycemic control and weight loss through 3 years","volume":"60(Suppl. 1)","author":"MacConell","year":"2011","journal-title":"Diabetes"},{"key":"2022031220062681300_B27","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1210\/jc.2010-2081","article-title":"DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes","volume":"96","author":"Blevins","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031220062681300_B28","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2337\/dc10-1900","article-title":"Exenatide twice daily versus premixed insulin aspart 70\/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia","volume":"34","author":"Gallwitz","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031220062681300_B29","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3810\/pgm.2010.05.2149","article-title":"Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes","volume":"122","author":"Blevins","year":"2010","journal-title":"Postgrad Med"},{"key":"2022031220062681300_B30","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1463-1326.2011.01366.x","article-title":"The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight\/obese patients with type 2 diabetes: the EGO study","volume":"13","author":"Umpierrez","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2022031220062681300_B31","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":"Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial","volume":"52","author":"Russell-Jones","year":"2009","journal-title":"Diabetologia"},{"key":"2022031220062681300_B32","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.clinthera.2006.10.020","article-title":"Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes","volume":"28","author":"Philis-Tsimikas","year":"2006","journal-title":"Clin Ther"},{"key":"2022031220062681300_B33","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.clinthera.2008.11.001","article-title":"A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes","volume":"30","author":"Hollander","year":"2008","journal-title":"Clin Ther"},{"key":"2022031220062681300_B34","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00125-007-0911-x","article-title":"A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes","volume":"51","author":"Rosenstock","year":"2008","journal-title":"Diabetologia"},{"key":"2022031220062681300_B35","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.2337\/dc09-2294","article-title":"A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs","volume":"33","author":"Swinnen","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031220062681300_B36","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1463-1326.2012.01560.x","article-title":"GLP-1 based therapies: differential effects on fasting and postprandial glucose","volume":"14","author":"Fineman","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2022031220062681300_B37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1464-5491.2009.02899.x","article-title":"A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes","volume":"27","author":"Fogelfeld","year":"2010","journal-title":"Diabet Med"},{"key":"2022031220062681300_B38","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/dmrr.989","article-title":"Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes","volume":"25","author":"Raskin","year":"2009","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031220062681300_B39","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1185\/03007990903223739","article-title":"Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes","volume":"25","author":"Hompesch","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"2022031220062681300_B40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1185\/030079908X242755","article-title":"Improving glycemic control with insulin detemir using the 303 Algorithm in insulin na\u00efve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study","volume":"24","author":"Selam","year":"2008","journal-title":"Curr Med Res Opin"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/5\/1368\/615302\/1368.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/5\/1368\/615302\/1368.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T21:54:30Z","timestamp":1647122070000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/36\/5\/1368\/29587\/Once-Weekly-Exenatide-Versus-Once-or-Twice-Daily"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,13]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,4,13]]},"published-print":{"date-parts":[[2013,5,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc12-1333","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,13]]}}}